NeoGenomics is trading down 4.02% at $17.22 on October 30, 2026, with no company-specific news explaining the decline surfaced in available reporting.
- Third-quarter revenue rose 11% to $209 million, and NeoGenomics raised full-year guidance.
- Healthcare was reported higher premarket, while recent analyst actions included price-target increases and Buy ratings; neither supports a clear explanation for the same-day drop.